Peter Foley

11.7k total citations · 5 hit papers
175 papers, 6.6k citations indexed

About

Peter Foley is a scholar working on Dermatology, Immunology and Epidemiology. According to data from OpenAlex, Peter Foley has authored 175 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Dermatology, 81 papers in Immunology and 43 papers in Epidemiology. Recurrent topics in Peter Foley's work include Psoriasis: Treatment and Pathogenesis (76 papers), Dermatology and Skin Diseases (64 papers) and Nonmelanoma Skin Cancer Studies (30 papers). Peter Foley is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (76 papers), Dermatology and Skin Diseases (64 papers) and Nonmelanoma Skin Cancer Studies (30 papers). Peter Foley collaborates with scholars based in Australia, United States and Germany. Peter Foley's co-authors include Kenneth B. Gordon, Robin Marks, Kristian Reich, Yaung‐Kaung Shen, Kim Papp, Michael Song, Graham G. Giles, Christopher Baker, April W. Armstrong and Yasmine Wasfi and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Peter Foley

162 papers receiving 6.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

2017 537 citations Kristian Reich, April W. Armstrong et al. profile →
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus

2006 462 citations Nicole Basset‐Séguin, Peter Foley et al. profile →
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

2018 452 citations Kenneth B. Gordon, Bruce Strober et al. profile →
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

2022 173 citations Bruce Strober, Diamant Thaçi et al. profile →
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

2021 170 citations Kenneth B. Gordon, Peter Foley et al. profile →

Peers

Countries citing papers authored by Peter Foley

Since Specialization

Citations

This map shows the geographic impact of Peter Foley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Foley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Foley more than expected).

Fields of papers citing papers by Peter Foley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Foley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Foley. The network helps show where Peter Foley may publish in the future.

Co-authorship network of co-authors of Peter Foley

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Foley. A scholar is included among the top collaborators of Peter Foley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Foley. Peter Foley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy 2025 ·Dermatology and Therapy ·(unknown), Thomas Bieber, Amy S. Paller, Lisa A. Beck, Masahiro Kamata, L. Puig, Marni Wiseman, Khaled Ezzedine, Alan D. Irvine, Peter Foley, J.Q. Del Rosso, Linda Stein Gold, (unknown), Martín Dossenbach, Gaia Gallo, (unknown), Marta Casillas, (unknown), (unknown), Raj Chovatiya	7
2	Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis 2025 ·Clinical and Experimental Dermatology ·Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Tiago Torres, Zoran Popmihajlov, Ying-Ming Jou, Misti Linaberry, (unknown), C.E.M. Griffiths	0
3	Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2) 2024 ·Journal of the European Academy of Dermatology and Venereology ·Bruce Strober, Andrew Blauvelt, Richard B. Warren, Kim Papp, April W. Armstrong, Kenneth B. Gordon, Akimichi Morita, Andrew Alexis, Mark Lebwohl, Peter Foley, Renata M. Kisa, Elizabeth Colston, Tao Wang, Subhashis Banerjee, Diamant Thaçi	27
4	Asia‐Pacific consensus recommendations on the management of generalized pustular psoriasis 2024 ·The Journal of Dermatology ·Siew Eng Choon, Peter Foley, Pravit Asawanonda, Hideki Fujita, Seong Jin Jo, Yuling Shi, Colin Theng, Azura Mohd Affandi, Chul Hwan Bang, (unknown), Yu‐Huei Huang, Le Huu Doanh, Tae‐Gyun Kim, Akimichi Morita, Hazel H. Oon, Pablo Fernández‐Peñas, Natta Rajatanavin, (unknown), (unknown), Tsen‐Fang Tsai	3
5	Pharmaceutical Management of Rosacea—An Australian/New Zealand Medical Dermatology Consensus Narrative 2024 ·Dermatologic Therapy ·Marius Rademaker, Peter Foley, John Sullivan, Kathy Armour, Christopher Baker, A Ferguson, Kurt Gebauer, (unknown), Gillian Marshman, Erin McMeniman, Diana Rubel, (unknown)	0
6	Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials 2024 ·Journal of Dermatological Treatment ·Neil J. Korman, Richard B. Warren, Jerry Bagel, April W. Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, (unknown), Renata M. Kisa, Subhashis Banerjee, Andrew Blauvelt	1
7	Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis 2024 ·Journal of Allergy and Clinical Immunology ·Stephan Weidinger, Andrew Blauvelt, Kim Papp, Adam Reich, Chih‐Hung Lee, Margitta Worm, Charles Lynde, Yoko Kataoka, Peter Foley, Xiaodan Wei, Wanling Wong, (unknown), Christine Weber, (unknown), Sonya Davey, Fabrice Hurbin, (unknown), Karl Yen, John T. O’Malley, Charlotte Bernigaud	12
8	Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials 2023 ·British Journal of Dermatology ·Andrew Blauvelt, Diamant Thaçi, Kim Papp, Vincent Ho, Kamran Ghoreschi, Byung‐Soo Kim, Megan Miller, Yaung‐Kaung Shen, Yin You, Daphne Chan, (unknown), Ya‐Wen Yang, Mark Lebwohl, Alice B. Gottlieb, Jeffrey Crowley, Peter Foley	8
9	Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies – Adult patients 2023 ·Australasian Journal of Dermatology ·Peter Foley, Kurt Gebauer, John Sullivan, Erin McMeniman, Stephen Shumack, (unknown), (unknown), (unknown), Shireen Sidhu, Dev Tilakaratne, (unknown), (unknown), Peter Nash, Christopher Baker	5
10	Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial 2023 ·SKIN The Journal of Cutaneous Medicine ·Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, (unknown), Renata M. Kisa, Subhashis Banerjee, C.E.M. Griffiths	1
11	Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study 2023 ·British Journal of Dermatology ·Joseph F. Merola, Albert S. Chiou, Emmanuel During, Antonio Costanzo, Peter Foley, (unknown), (unknown), Andreas Pinter, Roni P. Dodiuk‐Gad, Dagmar Simon, M. Tauber, Richard Weller, J Rodríguez, Marius Ardeleanu, (unknown), Zafer E. Ozturk	13
12	Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance 2022 ·Journal of the European Academy of Dermatology and Venereology ·Kristian Reich, Kenneth B. Gordon, Bruce Strober, Richard G. Langley, Megan Miller, Ya‐Wen Yang, Yaung‐Kaung Shen, Yin You, Yaowei Zhu, Peter Foley, Andrew Blauvelt	20
13	Direct-to-Consumer Testing for Routine Purposes 2022 ·Clinical Chemistry ·(unknown), Dina N. Greene, Stacy G. Beal, Peter Foley, Anthony A. Killeen, (unknown), (unknown)	6
14	Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials 2021 ·Dermatology and Therapy ·C.E.M. Griffiths, Marjolein de Bruin‐Weller, Mette Deleuran, Maria Concetta Fargnoli, D. Staumont‐Sallé, Chih-ho Hong, (unknown), Peter Foley, Seong Jun Seo, Jérôme Msihid, Zhen Chen, Sonya Cyr, Ana B. Rossi	21
15	Efficacy and Safety of a Potent and Highly Selective Oral Tyrosine Kinase 2 Inhibitor, BMS-986165, in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase II, Randomized, Placebo-Controlled Trial 2018 ·Arthritis & Rheumatism ·Kim Papp, Kenneth B. Gordon, Diamant Thaçi, Akimichi Morita, Melinda Gooderham, Peter Foley, Ihab Girgis, Sudeep Kundu, Subhashis Banerjee	1
16	LONG-TERM EFFICACY OF GUSELKUMAB TREATMENT AFTER DRUG WITHDRAWAL AND RETREATMENT IN PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS: RESULTS FROM VOYAGE 2 2018 ·(unknown), April W. Armstrong, Peter Foley, Yasmine Wasfi, Michael Song, Yaung‐Kaung Shen, Shu Li, Ernesto J. Muñoz‐Elías, B. Randazzo, Kristian Reich	3
17	Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P) 2018 ·British Journal of Dermatology ·Richard G. Langley, Kim Papp, Melinda Gooderham, (unknown), Craig Mallinckrodt, Noah Agada, Andrew Blauvelt, Peter Foley, (unknown), (unknown)	48
18	EFFICACY AND SAFETY OF RISANKIZUMAB: RESULTS FROM TWO DOUBLE-BLIND, PLACEBO- AND USTEKINUMAB-CONTROLLED, PHASE 3 TRIALS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS 2018 ·Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim Papp, Howard Sofen, L. Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin Valdes, Elizabeth H. Thompson, H. Bachelez	10
19	Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice 2017 ·British Journal of Dermatology ·Arnon D. Cohen, Jashin J. Wu, L. Puig, Sergio Chimenti, Ronald Vender, Murlidhar Rajagopalan, Ricardo Romiti, Claudia de la Cruz, Lone Skov, Claus Zachariae, Helen Young, Peter Foley, Joelle M. van der Walt, Luigi Naldi, Errol P. Prens, Andrew Blauvelt	33
20	Adherence to topical therapies in actinic keratosis: A literature review 2016 ·Journal of Dermatological Treatment ·Peter Foley, Eggert Stockfleth, Ketty Peris, Nicole Basset‐Séguin, R. Cerio, José Antônio Sanches, Carlos Guillén, Emily Farrington, Mark Lebwohl	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact